Lornoxicam for injection 8mg
Indications:Acute moderate post-operative pain and pain associated with acute lumbar and sciatica.
Dosage:Intramuscular (>5 seconds) or intravenous (>15 seconds) injection. Before injection, this product must be dissolved with 2ml of water for injection. Intravenous injection should be diluted with no less than 2ml of 0.9% NaCl injection. The conventional dose of this product is: the starting dose is 8mg. If 8 mg does not provide sufficient pain relief, 8 mg can be added once. In some cases, an additional 8 mg may be required on the first postoperative day, i.e., the maximum dose on the day is 24 mg. Thereafter, the dose of this product is 8mg, 2 times a day. The daily dose should not exceed 16 mg.
Adverse reactions:Adverse reactions with an incidence of more than 10%: no injection site-related adverse reactions (such as pain, redness, tingling, nervousness), stomach pain, nausea, vomiting, dizziness, drowsiness, worsening of drowsiness, headache, skin flushing. Adverse reactions with an incidence of less than 1% are: flatulence, agitation, dyspepsia, diarrhea, increased blood pressure, palpitations, chills, excessive sweating, dysgeusia, dry mouth, leukopenia, thrombocytopenia, and urination disorders.
[Contraindications] 1. Those who are allergic to lornoxicam are prohibited; 2. It is forbidden for those who are allergic to non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid); 3. Patients with hemorrhagic constitution, coagulation disorder or risk of bleeding during surgery or unsound coagulation mechanism are prohibited; 4. Acute gastric/intestinal bleeding or acute gastric or intestinal ulcer is contraindicated; 5. Moderate to severe renal impairment is disabled; 6. Prohibited for patients with cerebral hemorrhage or suspected cerebral hemorrhage; 7. It is forbidden for patients with large blood loss or dehydration; 8. Disabled for patients with severe impairment of liver function; 9. Disabled for patients with severe impairment of cardiac function;
[Precautions] 1. For patients with the following conditions, this product can only be used for special cases: (1) patients with impaired liver and kidney function (2) patients with a history of gastrointestinal bleeding or duodenal ulcer; (3) Coagulation disorders; 2. Exceed the prescribed dose. A dosage greater than the recommended dosage does not increase the efficacy of this product, on the contrary, it may cause adverse reactions.
Medication for special populations:Precautions during pregnancy and lactation:
Do not use in pregnant or lactating patients.
Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.
The products have been sold to some countries and regions in South America, Africa, and Asia.
Audited Supplier 
){kind=link}